Advancements in gastrointestinal treatments and public health metrics highlight recent medical research and clinical developments.

The FDA has approved the use of Stelara (ustekinumab) for pediatric patients with ulcerative colitis, marking it as the first non-TNF-targeting biologic available for both this condition and Crohn's disease.

A prospective Danish study discovered that radiological primary sclerosing cholangitis (PSC) is present in nearly 10% of patients at the time of their inflammatory bowel disease diagnosis.

A recent meta-analysis indicates that fiber supplementation, particularly psyllium, can improve clinical response rates for adults suffering from irritable bowel syndrome compared to placebo.

Clinical research found that daily colchicine administration provides no significant reduction in knee pain for patients suffering from osteoarthritis when compared to placebo groups.

A targeted hospital quality improvement program centered on MRSA prevention has successfully reduced the frequency of hospital-onset methicillin-resistant Staphylococcus aureus bacteremia.

Research highlights that premature infants diagnosed with congenital heart disease face a higher risk of impaired cognitive and motor development compared to those born at term.

Official figures show the fertility rate in England and Wales dropped to a record low of 1.39 in 2025, with the City of London and Cambridge reporting the lowest individual rates.

Healthcare systems are increasingly focusing on leadership, work-life balance, and professional development opportunities to address the factors driving physician retention and turnover.